We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostic and Therapeutic Use of Microbiota to Soon Become Reality

By LabMedica International staff writers
Posted on 18 Jun 2025

Despite the growing body of research linking the gut microbiome to a range of diseases, its clinical application remains limited due to biological complexity, methodological constraints, and gaps in communication between researchers and physicians. More...

The microbiome holds promise for diagnostics, such as colon cancer screening and predicting immunotherapy response, as well as for therapeutic uses like microbiota transplants and engineered probiotics. A new article published in Cell outlines a roadmap to bridge these challenges and guide doctors in translating microbiome research into real-world clinical practice.

The article, authored by a team of physician-scientists from Agostino Gemelli University Policlinic (Rome, Italy) and the Catholic University (Milan, Italy), aims to serve as a practical reference for clinicians. It summarizes current knowledge from microbiome studies and outlines how these insights can be applied in diagnostics and treatment. It also addresses the key barriers preventing this progress: a lack of standardization, inadequate clinical trial design, limited large-scale studies, and a cultural gap in clinician familiarity with microbiome science. According to the authors, the microbiome’s diagnostic and therapeutic potential is broad but remains underused due to difficulties in establishing direct causal links between microbiota composition and disease. Variability in individual microbiomes and external factors like diet and medication use complicate clinical study design.

Moreover, there is a lack of harmonized testing protocols, and most studies are single-center and small-scale, restricting wider application. The authors also note a major gap in interdisciplinary communication, which slows translation of lab research into clinical use. However, several promising applications are now approaching clinical viability. In diagnostics, microbiota composition could soon serve as a biomarker for early disease detection, particularly in colon cancer. It may also help distinguish between conditions such as ulcerative colitis and Crohn’s disease or predict a patient’s response to immunotherapy, especially in lung cancer and melanoma. On the therapeutic front, microbiota transplantation—already in use for Clostridium difficile infections—is evolving toward refined microbial cocktails. Other avenues include the use of lytic bacteriophages to target drug-resistant bacteria and engineered probiotics that produce or deliver therapeutic compounds.

To accelerate the adoption of microbiome-based tools, the authors propose several concrete actions: standardizing microbiota test reporting across labs, improving clinical trial design, aligning basic research with clinical needs, and training doctors to interpret and use microbiome data. Among the first expected clinical applications is a colon cancer screening test combining fecal occult blood testing with microbiota analysis to guide decisions about colonoscopy. Similarly, a test to predict cancer immunotherapy response based on microbiota profiles is also nearing readiness for clinical use. On the therapeutic front, future targets include using microbiota to eradicate multidrug-resistant infections such as intestinal Klebsiella, particularly in high-risk patients awaiting organ transplants. Over the long term, microbiome alterations could help boost the effectiveness of immunotherapies in cancer care.

“Despite a huge amount of research and studies on the microbiome, clinical applications are still very scarce, sometimes not entirely orthodox, sometimes “primitive”, said Dr. Gianluca Ianiro, researcher in Gastroenterology at the Catholic University and medical director of the Gastroenterology Unit at the Gemelli IRCCS Polyclinic. “But this will soon change, because the microbiome is the perfect target for precision medicine, specific to each individual and variable in composition depending on life events and diet."


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Rapid AKI Test
Acute Kidney Injury (AKI) Array (4-plex)
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.